Results 381 to 390 of about 2,123,606 (402)
Some of the next articles are maybe not open access.
Targeted Molecular Therapy in Melanoma
Seminars in Cutaneous Medicine and Surgery, 2010Immunotherapy and chemotherapy benefit few patients with metastatic melanoma, and even fewer experience durable survival benefit. These poor results may come from treating all melanomas as though they are biologically homogeneous. Recently, it has been shown that targeting specific activated tyrosine kinases (oncogenes) can have striking clinical ...
Keith T. Flaherty, Igor Puzanov
openaire +3 more sources
Molecular Targets of Antiviral Therapy
New England Journal of Medicine, 1989THE development of specific antiviral drugs that are minimally toxic to normal cells has ushered in a new era of antiviral therapy.
Jeffrey S. Flier +2 more
openaire +2 more sources
Molecular Targets and Targeted Therapies for Malignant Mesothelioma
Current Medicinal Chemistry, 2008Malignant mesothelioma is a highly invasive tumor originating from the mesothelial linings of the pleura, peritoneum and pericardium. It is seldom amenable to surgical intervention and poorly responsive to radiotherapy, leaving chemotherapy as the main therapeutic option for most patients. The development of effective drug regimens against mesothelioma
PALUMBO, CAMILLA +3 more
openaire +4 more sources
2017
Defining potential molecular targets for sepsis therapeutics has proven to be a real challenge in translating laboratory findings into effective clinical treatments. A myriad of possible targets have been proposed from preclinical studies but they often have overlapping pathologic functions, can differ depending upon the causative microbial pathogen ...
Andre C. Kalil, Steven M. Opal
openaire +2 more sources
Defining potential molecular targets for sepsis therapeutics has proven to be a real challenge in translating laboratory findings into effective clinical treatments. A myriad of possible targets have been proposed from preclinical studies but they often have overlapping pathologic functions, can differ depending upon the causative microbial pathogen ...
Andre C. Kalil, Steven M. Opal
openaire +2 more sources
Therapeutic apheresis and dialysis, 2018
The prognosis of metastatic or relapsed renal cell carcinoma (RCC) or bladder cancer (BC) remains poor despite the introduction of immune checkpoint blockade agents. We aimed to investigate the safety and the feasibility of a vaccination with WT1 peptide‐
M. Ogasawara, Mamiko Miyashita, S. Ota
semanticscholar +1 more source
The prognosis of metastatic or relapsed renal cell carcinoma (RCC) or bladder cancer (BC) remains poor despite the introduction of immune checkpoint blockade agents. We aimed to investigate the safety and the feasibility of a vaccination with WT1 peptide‐
M. Ogasawara, Mamiko Miyashita, S. Ota
semanticscholar +1 more source
Molecular targets in cancer therapy
Seminars in Oncology Nursing, 2003To review selected pharmacologic agents that target key cellular processes along with their mechanisms of action and adverse events. Nursing implications including what patients and families need to know, administration issues, and management of common toxicities will be reviewed.Research articles, clinical trials, abstracts, and book chapters ...
openaire +3 more sources
Targeted molecular therapy of malignant gliomas
Current Neurology and Neuroscience Reports, 2005Malignant gliomas are the most common form of primary brain tumors in adults. Despite advances in diagnosis and standard therapies such as surgery, radiation, and chemotherapy, the prognosis remains poor. Recent scientific advances have enhanced our understanding of the biology of gliomas and the role of tyrosine kinase receptors and signal ...
Patrick Y. Wen +4 more
openaire +5 more sources
Principles of Molecular Targeting for Radionuclide Therapy
2022Molecular targeting requires assessing several factors that come into play such as the location of the target, the choice of radionuclide, the inertness of the bifunctional chelate and stability of the covalently bound halogens, matching the residence time in the tumor with the physical half-life of the radionuclide, the scale and scope of the disease,
Bartoli F. +4 more
openaire +2 more sources
Molecular-Targeted Therapy for Melanoma
2011Cutaneous melanoma is an aggressive tumor, with a poor prognosis for patients with advanced disease and resistance to current therapies. Both the RAS/RAF/MEK/ERK (mitogen-activated protein kinase [MAPK]) and the PI3K/AKT signaling pathways have become crucial targets for pharmacological development, being constitutively activated through multiple ...
RUSSO AE +4 more
openaire +2 more sources
Molecular targets in cancer therapy
Expert Review of Anticancer Therapy, 201324th EORTC-NCI-AACR Symposium on ‘Molecular Targets and Cancer Therapeutics’6–9 November 2012, Dublin, IrelandThe EORTC-NCI-AACR Symposium is an annual meeting, jointly hosted by the European Organization for Research and Treatment of Cancer, the US National Cancer Institute and the American Association for Cancer Research, to encourage exchange of ...
James H. Doroshow, Shivaani Kummar
openaire +2 more sources